tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Mayank Mamtani, 241 are a BUY (89.26%), 27 are a HOLD (10%), 2 are a SELL (0.74%).
Analyst Mayank Mamtani, currently employed at B. RILEY, carries an average stock price target met ratio of 32.77% that have a potential upside of 50.22% achieved within 118 days.
Mayank Mamtani’s has documented 543 price targets and ratings displayed on 43 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CYTK, Cytokinetics at 10-Nov-2025.
Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for ALT (ALTIMMUNE) at 11/9/2023. The price target of $8 was fulfilled within 39 days with a profit of $5.55 (226.53%) receiving and performance score of 58.08.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$12
$8.63 (256.08%)
$12
1 years 2 months 19 days ago
(26-Sep-2024)
0/2 (0%)
$8.93 (290.88%)
Buy
$2.5
$-0.28 (-10.07%)
2 years 10 months ago
(15-Feb-2023)
1/1 (100%)
$1.86 (290.63%)
145
Buy
$30
3 years 5 months 23 days ago
(22-Jun-2022)
0/2 (0%)
$22.32 (290.63%)
Hold
$12
$8.63 (256.08%)
5 years 3 months 13 days ago
(02-Sep-2020)
1/2 (50%)
$1.58 (15.16%)
19
Buy
5 years 3 months 14 days ago
(31-Aug-2020)
0/1 (0%)
$59.52 (163.16%)
Which stock is Mayank Mamtani is most bullish on?
Which stock is Mayank Mamtani is most reserved on?
What Year was the first public recommendation made by Mayank Mamtani?
